BrainScope Company, Inc.

BrainScope Company, Inc. (BrainScope) is a medical neuro-technology firm utilizing EEG technology to assess the full spectrum of mild traumatic brain injury (mTBI), including functional injuries (such as a concussion), and structural injuries (such as a brain bleed). BrainScope was founded in 2006 and is headquartered in Bethesda, Maryland.
BrainScope's markets include the military, emergency departments, urgent care clinics, and both collegiate and professional level sports programs.
Technology.
"BrainScope One" is a multimodal assessment tool that provides clinicians with the ability to identify both the structural and functional sides of mild traumatic brain injuries (mTBIs) in their patients. The device utilizes electroencephalographic (EEG) technology, as well as cognitive performance and clinical assessments commonly used in mTBI evaluation.
The electroencephalographic (EEG) data that is collected with a disposable electrode headset provides objective biomarkers to both predict the likelihood that a patient's structural brain injury would be visible on a CT scan and assess the likelihood of functional impairment in the brain by comparing the patient's brain function to that of non-head injured individuals. "BrainScope One" also includes neurocognitive tests (Procedural Reaction Time & Match to Sample), which are performed by the patient on the device, as well as an extensive library of digitized concussion assessments.
An independent validation trial conducted using "BrainScope One" determined that the device's sensitivity to "≥1 mL of blood was ... 98.6%" and that its accurate CT-scan predictions can lead to a "reduction in the number of false positives of 33%."
"BrainScope One's" technology was created through 21 clinical studies at over 55 clinical sites spanning a decade, contributing to 23 investigator-initiated peer-review journal articles and resulting in 5 FDA clearances. "BrainScope One" is FDA cleared as an Rx-only device for use on patients 18–85 years of age who have suffered a mild head injury (Glasgow Coma Scale score of 13-15 and mTBI) within the previous 72 hours. "BrainScope One" was originally cleared by the FDA as the Ahead 300 under 510(k) K161068 in September 2016. Subsequent modifications to device Indications for Use regarding concussion/mTBI capabilities were FDA cleared under 510(k) K181179 in May 2018.
The company initiated a clinical research study on patients 13–25 years of age in May 2018 as part of its initiative to "introduce a teenage-focused product in the near-term."
Partners.
BrainScope has raised over $60 million in private capital and has received $30 million in research contracts, including funding from the United States Department of Defense and General Electric and the National Football League through their Head Health Challenge competition. Among the company's private investors are Revolution LLC, an investment firm founded by AOL co-founder Steve Case; DBL Partners, a venture capital firm that also backs Tesla and Pandora; and the Maryland Venture Fund.
BrainScope's other development partners include New York University School of Medicine and Johns Hopkins University and its clinical partners include Emory University, the University of Virginia and Washington University in St. Louis.